Long-term efficacy and tolerability of brivaracetam in pediatric patients with focal-onset seizures and cognitive or learning comorbidities: Post hoc analysis of an open-label trial
These data indicate that brivaracetam could be an efficacious and well-tolerated treatment option for pediatric patients with FOS with and without CLC. Behavior and executive functioning were generally stable or slightly improved in patients with and without CLC.
Authors
- Sami Elmoufti
- Brian D. Moseley (ORCID: https://orcid.org/0000-0001-8573-7340)
- Dimitrios Bourikas (ORCID: https://orcid.org/0009-0005-4503-0734)
- Juliane Koch
- Christine de la Loge (ORCID: https://orcid.org/0000-0002-5896-5927)
- Lieven G. Lagae (ORCID: https://orcid.org/0000-0002-7118-0139)
- Svetlana Dimova (ORCID: https://orcid.org/0000-0001-7014-0007)
Institutions
- University of Piraeus (GR)
- Urban College of Boston (US)
- UCB Pharma (Germany) (DE)
- University of Charleston (US)
- UCB Pharma (Belgium) (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Epilepsy Research
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1016/j.eplepsyres.2024.107482
- Citations
- 2
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77